Marksans Pharma Ltd has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH for a total cash consideration of €892,384. The acquisition is a strategic move to expand Marksans Pharma's presence across regulated European markets by securing direct, owned market-access capabilities in the European Union. The transaction is expected to be completed by July 31, 2026.

ABCnow GmbH is a pharmaceutical wholesale and distribution company headquartered in Flensburg, Germany. It is primarily engaged in the marketing and distribution of over-the-counter (OTC) products in the German healthcare market. The target entity was incorporated in 2023 and achieved revenue of €510,215.60 in 2024 and €227,233.69 in 2025.

The acquisition will enable Marksans Pharma to utilize ABCnow GmbH's front-end sales and marketing infrastructure to market products manufactured in its India, UK, and USA regions. This integration is designed to bolster the company's presence in European markets and support its growth aspirations through a capable team of professionals in Germany.

The transaction involves a cash consideration and does not constitute a related party transaction. The shareholders of ABCnow GmbH are not related to Marksans Pharma, and the promoter or promoter group of the company holds no interest in the entity being acquired. No governmental or regulatory approvals are required for the completion of this acquisition.

Key Details of ABCnow GmbH

Marksans Pharma Ltd has fixed Thursday, August 20, 2026, as the record date to determine member eligibility for a final dividend of ₹0.90 per equity share. The Board of Directors recommended this dividend at its meeting held on May 26, 2026, for the financial year ended March 31, 2026. The payout is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM). If approved, the dividend will be paid on or after Thursday, September 10, 2026, subject to deduction of tax at source.

The 34th AGM is scheduled for Thursday, August 27, 2026, at 11:00 a.m. IST via Video Conferencing. The Board meeting to consider the AGM date and record date commenced at 11:15 a.m. and concluded at 11:50 a.m. on July 03, 2026. The Notice of AGM and the Annual Report for FY26 will be sent to members electronically and made available on the company's website.

Financial Performance

The company reported a consolidated net profit of ₹4,200.64 million for the year ended March 31, 2026, compared to ₹3,826.19 million in the prior year. Revenue from operations increased to ₹29,509.38 million from ₹26,228.45 million in FY25. The financial results for FY26 were audited by MSKA & Associates LLP, which expressed an unmodified opinion.

Key Developments

The Group operates a single reportable segment, Pharmaceuticals. During the year, the company incorporated two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. The consolidated financial statements include the results of 12 audited subsidiaries and 3 unaudited subsidiaries. The total assets of the company stood at ₹38,609.02 million as of March 31, 2026, compared to ₹32,396.32 million in the previous year.